When was Turnstone Biologics founded?

Turnstone Biologics was founded in 2015 and raised its 1st funding round within a year of its incorporation.

Where is Turnstone Biologics located?

Turnstone Biologics is headquartered in San Diego, United States.

How many employees does Turnstone Biologics have?

As of Mar 01, 2026, the latest employee count at Turnstone Biologics is 50 - 199.

Is Turnstone Biologics a funded company?

Turnstone Biologics is a funded company, having raised a total of $172M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Oct 28, 2015.

How much is Turnstone Biologics worth?

The last known valuation of Turnstone Biologics was $***** as of Jun 27, 2025.

When was the latest funding round of Turnstone Biologics?

Turnstone Biologics' latest funding was a $***** Series D round on Jun 29, 2021, with participation from 16 investors.

What is the annual revenue of Turnstone Biologics?

Annual revenue of Turnstone Biologics is between $10M and $50M as on Dec 31, 2023

Where does Turnstone Biologics rank among its competitors?

Turnstone Biologics ranks 450th amongst 3721 active competitors, of which 1285 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Senti Bio, which secured $40M in May, 2026.

Who are the top competitors of Turnstone Biologics?

Turnstone Biologics' top competitors include Jazz Pharmaceuticals, Alnylam and Sana Biotechnology. Among them, Senti Bio secured the most recent funding round in May, 2026.

Turnstone Biologics - 2026 Company Profile, Team, Funding, Competitors & Financials

Turnstone Biologics is an acquired company based in San Diego (United States), founded in 2015 by David Stojdl, Brain Lichty and John Bell. It operates as a Developer of oncolytic viral immunotherapies for cancer treatment. Turnstone Biologics has raised $172M in funding from investors like Orbimed, Versant Ventures and Point72, with last known valuation of $*****. The company has 3721 active competitors, including 1285 funded and 872 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Alnylam and Sana Biotechnology.

Company Details

Developer of oncolytic viral immunotherapies for cancer treatment. The company has a RIVAL pipeline derived from a viral immunotherapy platform, with the lead RIVAL-01 program, and the TIDAL pipeline derived from our cell therapy platform, with the lead TIDAL-01 program. Also, has developed a tumor-targeted oncolytic vaccine for the targeted expression of tumor-associated antigens and immunomodulatory agents to treat cancer and modulate the tumor environment.

Website: turnstonebio.com
Social
Email ID: *****@turnstonebio.com
Phone Number: +1 **********

Key Metrics

Founded Year

2015

Location

San Diego, United States

Stage

Acquired

Total Funding

$172M in 4 rounds

Latest Funding Round

Series D, Jun 29, 2021, $*****

Last Known Valuation

$***** as on Jun 27, 2025

Investors

Orbimed & 18 more

Ranked

450^th among 3721 active competitors

Annual Revenue

$10M - $50M as on Dec 31, 2023

Employee Count

50 - 199 as on Mar 01, 2026

Investment & Acquisitions

Myst Therapeutics

Similar Companies

Jazz Pharmaceuticals & 3571 more

Exit Details

Acquired by XOMA Corporation (Jun 27, 2025)

View Turnstone Biologics' full profile

Turnstone Biologics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Turnstone Biologics Corp CIN: 83-2909368 , United States, Active	Jul 11, 2019	$10M - $50M (As on Dec 31, 2023)	80 (As on Dec 31, 2023)	-

Turnstone Biologics got acquired by XOMA Corporation on Jun 27, 2025.

Click here to take a look at Turnstone Biologics's acquisition in detail

Turnstone Biologics has raised a total funding of $172M over 4 rounds. Its first funding round was on Oct 28, 2015. Its latest funding round was a Series D round on Jun 29, 2021 for $*****. 16 investors participated in its latest round. Turnstone Biologics has 19 institutional investors.

Here is the list of recent funding rounds of Turnstone Biologics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 29, 2021	1791285	Series D	6104268	9770139	5769929	8094781
Jan 04, 2019	1134738	Series C	5608584	1250413	6432119	6893479
Nov 02, 2016	4993427	Series B	6832863	6706783	Orbimed	F-Prime Capital & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of Turnstone Biologics's funding rounds and investors

The founders of Turnstone Biologics are David Stojdl, Brain Lichty and John Bell.

Here are the details of Turnstone Biologics' key team members:

David Stojdl: Co-Founder of Turnstone Biologics.
Contact Info: 1 email address
Brain Lichty: Co-Founder of Turnstone Biologics.
Contact Info: 1 email address
John Bell: Co-Founder of Turnstone Biologics.
Contact Info: 1 email address

View details of Turnstone Biologics's Founder profiles and Board Members

Turnstone Biologics' employee count trend

Turnstone Biologics has 50 - 199 employees as of Mar 26. Here is Turnstone Biologics's employee count trend over the years:

Employee count trend for Turnstone Biologics

Uncover Turnstone Biologics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Turnstone Biologics include Jazz Pharmaceuticals, Alnylam and Sana Biotechnology. Here is the list of Top 10 competitors of Turnstone Biologics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Bellevue Healthcare Trust ... & 13 others	79/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Google Ventures, Baillie Gifford & 17 others	75/100
4th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
7th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
8th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
9th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
10th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
450th	Turnstone Biologics 2015, San Diego (United States), Acquired	Developer of oncolytic viral immunotherapies for cancer treatment	$172M	Teralys Capital, Sectoral & 17 others	55/100